Comparison of different treatment options in oral lichen planus and oral submucous fibrosis

Correlation of clinical stage and expression of ALDH1, ALK1 AND CALR with response to treatment in OSMF and OL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/04/013147

Enrollment

Registered

2018-04-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Oral lichen planus

Interventions

Intervention1: Topical aloe vera gel (for oral lichen planus): Topical application of 500mg aloe vera extract capsules thrice daily for 8 weeks Intervention2: Topical aloe vera gel (for oral submucous

Eligibility

Inclusion criteria

Inclusion criteria: Clinically and histopathologically proven cases of oral lichen planus and oral submucous fibrosis.

Exclusion criteria

Exclusion criteria: 1. Patients not willing to participate 2. Undergoing alternative treatment for the same condition. 3. Severe uncontrolled systemic disease and pregnancy.

Design outcomes

Primary

Measure	Time frame
1. For oral lichen planus Evaluation of site score, severity score and activity score based on Escudier scale and burning sensation using VAS score 2. For oral submucous fibrosis Mouth opening, tongue protrusion, cheek flexibility and VAS scoreTimepoint: At the time of first visit and every 4 weeks till 9 months	—

Secondary

Measure	Time frame
Reporting of any malignant transformation over a period of 9 monthsTimepoint: individuals will be assessed every 4 weeks and in case of any suspicion, biopsy will be done	—

Countries

India

Contacts

Public ContactDr Girish Chand Bhatt

Mailana Azad Institute of Dental Sciences

drsunitagupta@yahoo.com9654700955

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 20, 2026